Company Overview and News
KUALA LUMPUR (June 22): Food packaging manufacturer SCGM Bhd's net profit plunged 97% to RM150,000 in the fourth financial quarter ended April 30, 2018 (4QFY18) from RM5.08 million a year ago, on higher resin prices, finance costs, depreciation charges, labour cost and foreign exchange losses incurred.
KUALA LUMPUR (June 22): 4G network operator Green Packet Bhd plans to raise as much as RM52.57 million via its proposal to undertake a renounceable rights issue on the basis of one rights share for every five existing shares held, together with warrants, on the basis of three warrants for every one rights share.
0082 BSMAF 1818
KUALA LUMPUR, June 22 — MY E.G. Services Bhd’s (MyEG) wholly-owned subsidiary, MY EG International Sdn Bhd, today incorporated a wholly-owned subsidiary that is intended to be the holding company for investments in Indonesia.
KUALA LUMPUR, June 22 — Malaysia Airports Holdings Bhd (MAHB) announced that today would be the last day of Datuk Mohd Badlisham Ghazali’s contractual tenure as MAHB Managing Director, a position he has held since June 23, 2014.
MYPRY BSMAF 5014 1818
KUALA LUMPUR, June 22 — The ringgit rebounded to close slightly higher against the US dollar today, as the greenback retreated from an 11-month high on profit taking after a recent rally, dealers said.
KUALA LUMPUR (June 22): Icon Offshore Bhd’s wholly-owned subsidiary Icon Offshore Group Sdn Bhd has bagged an RM23 million contract to provide a utility vessel to Hess Exploration and Production Malaysia BV for its operations.
BSMAF 5255 1818
KUALA LUMPUR (June 22): Today is the last day in service for Malaysia Airports Holdings Bhd (MAHB) managing director Datuk Mohd Badlisham Ghazali as his contract tenure has come to an end.
MYPRY BSMAF 5014 1818
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET